WallStSmart

BP PLC ADR (BP)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 70% more annual revenue ($327.80B vs $193.00B). NVO leads profitability with a 37.2% profit margin vs 1.7%. BP appears more attractively valued with a PEG of 0.05. NVO earns a higher WallStSmart Score of 74/100 (B).

BP

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.5Value: 7.3Quality: 5.0

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPUndervalued (+26.9%)

Margin of Safety

+26.9%

Fair Value

$52.77

Current Price

$43.34

$9.43 discount

UndervaluedFair: $52.77Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP3 strengths · Avg: 9.7/10
PEG RatioValuation
0.0510/10

Growing faster than its price suggests

EPS GrowthGrowth
474.5%10/10

Earnings expanding 474.5% YoY

Market CapQuality
$114.92B9/10

Large-cap with strong market position

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

BP4 concerns · Avg: 3.5/10
P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Return on EquityProfitability
5.8%3/10

ROE of 5.8% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, EPS Growth, Market Cap. Revenue growth of 11.6% demonstrates continued momentum. PEG of 0.05 suggests the stock is reasonably priced for its growth.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : BP

The primary concerns for BP are P/E Ratio, Price/Book, Return on Equity. Thin 1.7% margins leave little buffer for downturns.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

BP profiles as a value stock while NVO is a growth play — different risk/reward profiles.

NVO carries more volatility with a beta of 0.35 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 65/100), backed by strong 37.2% margins and 24.0% revenue growth. BP offers better value entry with a 26.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?